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Abstract
 
Giant cell arteritis (GCA) is a granulomatous and occlusive vasculitis that causes blindness,
stroke, and aortic aneurysm. CD4
 
 
 
 T cells are selectively activated in the adventitia of affected
arteries. In human GCA artery–severe combined immunodeficiency (SCID) mouse chimeras,
depletion of CD83
 
 
 
 dendritic cells (DCs) abrogated vasculitis, suggesting that DCs are critical
antigen-presenting cells in GCA. Healthy medium-size arteries possessed an indigenous popu-
lation of DCs at the adventitia–media border. Adoptive T cell transfer into temporal artery–
SCID mouse chimeras demonstrated that DCs in healthy arteries were functionally immature,
but gained T cell stimulatory capacity after injection of lipopolysaccharide. In patients with
polymyalgia rheumatica (PMR), a subclinical variant of GCA, adventitial DCs were mature
and produced the chemokines CCL19 and CCL21, but vasculitic infiltrates were lacking. Human
histocompatibility leukocyte antigen class II–matched healthy arteries, PMR arteries, and GCA
arteries were coimplanted into SCID mice. Immature DCs in healthy arteries failed to stimulate
T cells, but DCs in PMR arteries could attract, retain, and activate T cells that originated from
the GCA lesions. We propose that in situ maturation of DCs in the adventitia is an early event
in the pathogenesis of GCA. Activation of adventitial DCs initiates and maintains T cell responses
in the artery and breaks tissue tolerance in the perivascular space.
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Introduction
 
Giant cell arteritis (GCA) is a systemic vasculitis that affects
medium- and large-size arteries, most often the extracranial
branches of the aortic arch and the aorta itself (1, 2). Arteritic
lesions cause vascular stenosis and subsequent tissue isch-
emia (3). Severe complications of GCA include blindness,
stroke, and aortic arch syndrome. The diagnosis of GCA is
established by temporal artery biopsy, which typically
shows granulomatous infiltrates, multinucleated giant cells,
fragmentation of the elastic membranes, thinning of the
media, and occlusion of the vascular lumen (4). Inflammatory
lesions in GCA are composed of activated CD4
 
 
 
 T cells
and macrophages. Selected CD4
 
 
 
 T cells undergo expansion
in the artery, strongly suggesting antigen-driven responses
(5). IFN-
 
 
 
 has been identified as a key cytokine and plays a
critical role in regulating the effector functions of tissue-
infiltrating macrophages (6, 7). Macrophages are committed
to distinct and nonoverlapping functional pathways (8),
including the production of proinflammatory cytokines,
the release of reactive oxygen intermediates (9, 10), the
secretion of growth (11) and angiogenic factors (12), and the
production of nitric oxide synthase (13). Intimal hyperplasia,
the process that leads to vascular occlusion and ischemia, has
been closely linked to both oxidative (9) and nitrosative
stress (13) in the medial smooth muscle cell layer. Intimal
hyperplasia is also associated with high tissue production of
IFN-
 
 
 
 and the formation of multinucleated giant cells in
the arterial wall lesions (14).
Clonal expansion of selected CD4
 
 
 
 T cells in the vascular
wall suggests that adaptive immune responses drive the
chronic inflammatory reaction (5). Interestingly, IFN-
 
 
 
production by CD4
 
 
 
 T cells is limited to the arterial adventitia
(7). The physiologic role of the adventitia is directly linked
to the vasa vasorum, the capillary network supplying the
wall structure. Because the vessel wall is otherwise avascular,
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the adventitia provides the only physiologic port of entry
for T cells and macrophages into this structure. We have
found recently that the adventitia includes a cellular compo-
nent that predisposes it to supporting T cell responses. Nor-
mal temporal arteries have a population of resident DCs that
are positioned at the adventitia–media border (15). These
adventitial DCs reside outside the external elastic lamina,
which separates the adventitia from the smooth muscle cell–
rich tunica media. The DCs typically form a ring of den-
drites around the circumference of the artery. It is unknown
how these adventitial DCs contribute to immunosurveil-
lance, which types of antigens they sample, and which sig-
nals determine their maturation.
The spectrum of the GCA syndrome includes polymyal-
gia rheumatica (PMR), a variant that shares many clinical
and epidemiological features with GCA, but lacks its vascu-
litic and ischemic manifestations (6, 16, 17). PMR is a syn-
drome of muscle pain and stiffness that affects the neck,
shoulders, and pelvic girdle. PMR can be present in patients
with GCA, but PMR occurs more frequently in the absence
of fully developed GCA. In PMR, temporal artery speci-
mens do not show an appreciable mononuclear infiltrate or
any tissue damage by histological examination. However, a
minute number of activated T cells and macrophages can be
detected by reverse transcription–PCR (6).
Here, we report that activation of adventitial DCs is an
early and critical event in GCA that precedes the invasion
of T cells and macrophages. In normal arteries, adventitial
DCs are immature. In situ triggering of Toll-like receptors
(TLRs) is sufficient to induce the differentiation of DCs so
that they are capable of stimulating T cells. In arteries from
patients with PMR, adventitial DCs are no longer imma-
ture but are activated and capable of triggering T cells.
Highly activated, chemokine-producing DCs are essential
to maintain established GCA; depletion of CD83
 
 
 
 DCs ab-
rogates the disease process. These data suggest a critical role
of the innate immune system in the initiation and mainte-
nance of vasculitis and assign a gatekeeper function to spe-
cialized DCs positioned in the arterial adventitia.
 
Materials and Methods
 
Patients and Temporal Arteries. 
 
Temporal artery specimens
were collected from patients undergoing diagnostic temporal ar-
tery biopsy. 36 patients with typical histomorphology of GCA
and 30 patients with the diagnosis of PMR and lacking histomor-
phologic findings of vasculitis were enrolled. At the time of the
temporal artery biopsy, none of the patients were on 
 
 
 
10 mg qd
corticosteroids. 32 patients who had undergone diagnostic biopsy
for suspected GCA but who had neither PMR nor GCA served
as controls. Temporal arteries were divided into several sections
and were shock frozen for RNA analysis and embedded in OCT
compound (Sikura Fine-Tek) or in paraffin. The protocol was
approved by the Mayo Clinic Institutional Review Board, and all
patients gave informed consent.
 
Reagents. 
 
LPS (
 
Escherichia coli
 
, 0127:B8) and CFA were pur-
chased from Sigma-Aldrich. Human TNF-
 
 
 
 was obtained from
R&D Systems. Mouse anti-CD83 Ab (IgG1 
 
 
 
, clone HB15e;
Research Diagnostics) was used for in vivo experiments. The
specificity of this antibody has been described previously
(18, 19).
The following Abs were used for immunohistochemical pro-
cedures: mouse anti–human CD83 (1:1,000; Research Diag-
nostics), mouse anti–human CCL19 (1:300), goat anti–human
CCL21 (1:300; both obtained from R&D Systems), rabbit anti–
S-100 (1:500), mouse anti–human CD3 (1:300), mouse anti–
human fascin (1:100), mouse anti–human CD11c (1:100), goat
anti–rabbit Ig, rabbit anti–mouse Ig, and goat anti–mouse Ig (all
obtained from DakoCytomation).
 
Immunohistochemical Analysis. 
 
The Abs used in this work and
their optimal working dilutions have been described previously
(10, 13, 15). Paraffin-embedded samples were cut into 5-
 
 
 
m
sections and deparaffinized in 100% xylene. For fascin staining,
the deparaffinized tissue was steamed in citrate buffer for 30 min
to facilitate antigen recovery. Endogenous peroxidase activity
was blocked, and the sections were incubated in 5% goat serum
(Invitrogen). Slides were stained with anti–S-100 or anti–human
fascin Ab at room temperature (RT) for 1 h in a humidified
chamber. The sections were washed with tap water and incu-
bated at RT with biotin-conjugated goat anti–rabbit Ig Ab for
30 min. To stain for S-100, the slides were washed with tap wa-
ter and an avidin-biotinylated enzyme solution (ABC-peroxidase
kit; Vector Laboratories) was added for 30 min. Red staining was
produced using aminoethylcarbazole as the chromagen (Vector
Laboratories) for 20–30 min. The Vector ABC–alkaline phos-
phatase kit was used with Vector blue for fascin staining. Sec-
tions were counterstained with hematoxylin solution (Surgipath)
for 3 min.
OCT-embedded sections of temporal arteries were cut into
5-
 
 
 
m sections and fixed with acetone for 10 min, dried for 30
min, and soaked in 1% paraformaldehyde solution, pH 7.4, for 5
min. After blocking endogenous peroxidase and incubating with
5% normal rabbit or goat serum (Invitrogen), the sections were
stained for 1 h with unconjugated primary Ab followed by bio-
tin-conjugated rabbit anti–mouse or goat anti–mouse Ig Ab (30
min at RT). The sections were developed with ABC–alkaline
phosphatase using blue or red as chromagens (Vector Laborato-
ries) for CD83 or CCL19 detection, respectively, or with ABC-
peroxidase using 3,3
 
 
 
-diaminobenzidine as the chromagen for
CD3 and CD11c detection. The tissue sections were washed
with tap water, and the slides were counterstained with hematox-
ylin (Surgipath) for 3 min. For all staining experiments, control
stains with isotype-matched primary Ab were included. Tissue
sections were viewed by light microscopy and were photo-
graphed using a microscopic system (model LSM-510; Carl Zeiss
MicroImaging, Inc.).
 
PCR. 
 
Total cellular RNA was isolated using TRIzol re-
agent (Invitrogen), reverse transcribed into single-stranded cDNA
using avian myeloblastosis virus reverse transcriptase (Roche Ap-
plied Sciences), and amplified using specific primer pairs. Se-
quences of the primers used in the paper are listed in Table I. Op-
timal conditions for all primers were established by amplifying
cDNA samples from human PBMC-derived mature DCs, hu-
man-activated T cell clones, human tonsils, and activated human
PBMCs. TLR2 and TLR4 sequences were amplified using a
thermocycler (model 9600; PerkinElmer), and CD14, CD83,
CCL18, IL-18, CCL19, CCL21, and TCR 
 
 
 
-chain were ampli-
fied using an UNO II thermocycler (Biometra) using the follow-
ing conditions: 30 cycles of denaturation at 95
 
 
 
C for 60 s, primer
annealing at 55
 
 
 
C for 60 s, and primer extension at 72
 
 
 
C for 90 s.
The reaction products were visualized on ethidium bromide–
stained 1% LE or 3% MS agarose gels (both Roche Applied Sci- 
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ences) and digitally documented for further analysis (GelDoc
2000; Bio-Rad Laboratories).
The method to quantify tissue cytokine mRNA, including the
sequences of the primers and probes, has been described in detail
previously (20). mRNA for the chemokines CCL19 and CCL21,
the cytokines IFN-
 
 
 
 and IL-18, and the cell surface markers
CD83 and CD40L was quantified using the LightCycler PCR
(Roche Applied Sciences). 1 
 
 
 
l cDNA was diluted in a total vol-
ume of 20 
 
 
 
l of SYBR green master mix (Roche Applied Sci-
ences) as described previously (15). The PCR thermal cycling
was as follows: initial denaturation at 95
 
 
 
C for 30 s, followed by
40 cycles of amplification at 95
 
 
 
C for 0 s, 57
 
 
 
C for 7 s, and 72
 
 
 
C
for 16 s. Melting curve analysis was accomplished by 95
 
 
 
C for 0 s,
60
 
 
 
C for 30 s, and 95
 
 
 
C for 0 s. HLA-DRB1 alleles were deter-
mined from DNA as described previously (21).
 
Depletion of CD83
 
 
 
 DCs in GCA-SCID Mouse Chimeras.
 
All animal procedures were approved by the Mayo Clinic Institu-
tional Animal Care and Use Committee. Temporal artery–SCID
mouse chimeras were generated by implanting pieces of temporal
arteries from patients with GCA subcutaneously on the back of
NOD-SCID mice (Jackson Laboratories) as described previously
(10, 22, 23). Three to five mice were each implanted with tem-
poral artery from the same donor and assigned to the treatment
group or the control group. On days 9–11 after the implantation,
the mice were injected i.p. with 200 
 
 
 
g anti-CD83 Ab or with
control Ig each day. On day 17, the arterial grafts were recovered
and shock frozen in liquid nitrogen for mRNA analysis or em-
bedded in OCT compound and stored at 
 
 
 
80
 
 
 
C for immunohis-
tochemical analysis.
 
Activation of Arterial DCs in Vivo. 
 
Arteries obtained from in-
dividuals who had neither GCA nor PMR were implanted into
SCID mice in accordance with the standard protocol. 7–10 d af-
ter the implantation, the mice were injected i.v. with 2 
 
 
 
g TNF-
 
 
 
(2.2 
 
 
 
 10
 
5
 
 U), 10 
 
 
 
g LPS, or buffer control, or they were in-
jected i.p. with 100 
 
 
 
l CFA. 48 h after the injections, the artery
grafts were explanted. The tissue was shock frozen for mRNA
isolation or was embedded in OCT compound and stored at
 
 
 
80
 
 
 
C for immunohistochemical studies.
 
Adoptive Transfer of Alloreactive T Cells. 
 
Alloreactive T cell
clones were generated from an HLA-DR4
 
 
 
 donor by stimulation
with HLA-DRB1
 
*
 
0401
 
 
 
 stimulator cells and maintained as de-
scribed previously (24). Human T cell clones were used for adop-
tive transfer experiments 14 d after their last in vitro restimula-
tion. Temporal artery–SCID mouse chimeras were generated by
implanting pieces of normal temporal arteries that were free of
any inflammation into NOD-SCID mice. One artery was di-
vided into three pieces to be implanted into three mice that were
assigned to three different treatment arms. 6 d after implantation,
group 1 was injected i.v. with 10 
 
 
 
g LPS. Group 2 received con-
trol buffer. 30 h later, 5 
 
 
 
 10
 
6
 
 cells of the HLA-DRB1
 
*
 
0401-
specific human T cell clone were adoptively transferred into both
groups of mice. Group 3 served as a control and was treated with
control buffer on days 10 and 12. The arterial grafts were recov-
ered 18 d after the original implantation and 6 d after the adop-
tive transfer. Tissues were shock frozen for RNA analysis or
embedded in OCT compound and stored at 
 
 
 
80
 
 
 
C for immu-
nohistochemical studies.
 
Induction of a T Cell Response in Tissues from Patients with
PMR. 
 
Temporal artery specimens were selected from patients
who typed positive for the HLA-DRB1
 
*
 
0401 allele. Temporal
artery–SCID mouse chimeras were generated with noninflamed
arteries, arteries from patients with PMR, or arteries from pa-
tients with GCA. An additional group of mice received arteries
from all three sources, and the tissues were implanted into distinct
subcutaneous sites. The grafts were retrieved 7 d after the implan-
tation and analyzed for in vivo transcription by quantitative re-
verse transcription–PCR or by immunohistochemistry.
 
Statistical Analysis. 
 
Results from the quantitative reverse tran-
scription–PCR were compared using the Mann-Whitney Rank
Sum test, and the datasets of the cotransplantation experiments were
analyzed by the Student-Newman-Keuls method of the Friedman
Repeated Measures analysis of variance (SigmaStat; SPSS).
 
Results
 
A Resident Population of DCs in the Arterial Adventitia.
 
The adventitia functions as a support tissue for the vessel
and provides the vasa vasorum and the capillary network
that supply the wall structure with oxygen. In addition to
the microvessels, the adventitia is composed of fibroblasts
and it also contains a population of S-100
 
 
 
 cells (Fig. 1 A).
These S-100
 
 
 
 cells express fascin and CD11c (Fig. 1, B and
C) but not the monocyte/macrophage marker CD14,
which is consistent with the phenotype of DCs. Adventitial
DCs form a ring of extended dendrites at the outer edge of
 
Table I.
 
Primer Sequences
 
CD14 5
 
 
 
-CACACTCGCCTGCCTTTTCC-3
 
 
 
5
 
 
 
-GATTCCCGTCCAGTGTCAGG-5
 
 
 
CD40L 5
 
 
 
-GAAGGTTGGACAAGATAGAAGATG-3
 
 
 
5
 
 
 
-GCCCACTGTAACACAGATGTTG-3
 
 
 
CD83 5
 
 
 
-GTTATTGGAGGGTGGTGAAGAGAGG-3
 
 
 
5
 
 
 
-GTGAGGAGTCACTAGCCCTAAATGC-3
 
 
 
CCL18 5
 
 
 
-GGTGTCATCCTCCTAACCAAG-3
 
 
 
5
 
 
 
-GGAAAGGGGAAAGGATGATA-3
 
 
 
CCL19 5
 
 
 
-CCAATGATGCTGAAGACTGCT-3
 
 
 
5
 
 
 
-GCCAAGATGAAGCGCCGCA-3
 
 
 
CCL21 5
 
 
 
-CCCCAGGACCCAAGGCAGTGATGGA-3
 
 
 
5
 
 
 
-TGCAAGAGGACTGAGCGGTCACA-3
 
 
 
IFN-
 
 
 
5
 
 
 
-ACCTTAAGAAATATTTTAATGC-3
 
 
 
5
 
 
 
-ACCGAATAATTAGTCAGCTT-3
 
 
 
IL-18 5
 
 
 
-GACCAAGTTCTCTTCATTGACCA-3
 
 
 
5
 
 
 
-ATGTTATCAGGAGGATTCATTTC-3
 
 
 
TLR2 5
 
 
 
-GGCCAGCAAATTACCTGTGTG-3
 
 
 
5
 
 
 
-AGGCGGACATCCTGAACCT-3
 
 
 
TLR4 5
 
 
 
-CTGCAATGGATCAAGGACCA-3
 
 
 
 
5
 
 
 
-TTATCTGAAGGTGTTGCACATTCC-3
 
 
 
 
-Actin 5 -ATGGCCACGGCTGCTTCCAGC-3 
5 -CATGGTGGTGCCGCCAGACAG-3 Dendritic Cells in Giant Cell Arteritis 176
the external elastic lamina. They lack CD83 (Fig. 1 D), in-
dicating that they are in a resting state (19). Each arterial
cross section contains 20–25 DCs. This DC population is
constant in number and morphology in patients who un-
dergo temporal artery biopsy to rule out vasculitis and who
have neither GCA nor PMR.
In temporal arteries with vasculitis, DCs are greatly in-
creased in number, acquire the CD83 activation marker,
and populate the adventitia and also the media (15). They
travel with the granulomatous infiltrates (Fig. 1 E). Pheno-
typing of arterial DCs in a cohort of temporal artery biop-
sies demonstrated that activated CD83  DCs were also
present in a subset of patients who lacked inflammatory in-
filtrates and who were diagnosed by a pathologist as not
having vasculitis. Clinical analysis revealed that all patients
with noninflamed arteries but with CD83  DCs in the ad-
ventitia had PMR (Fig. 1 F).
The functional capabilities of DCs change fundamentally
as the cells make the transition from the resting to the acti-
vated state. To examine the functional profile of vascular
DCs in situ, we semi-quantified the production of chemo-
kine transcripts in tissue extracts collected from 12 normal
arteries, 18 arteries from patients with PMR, and 16 arter-
ies from patients with GCA. As shown in Fig. 2, normal ar-
teries were negative for CCL19-specific transcripts and ex-
pressed a low level of CCL21-specific sequences (median
of 202 copies). In noninflamed arteries, there were no cells
that stained with CCL19- or CCL21-specific Ab (unpub-
lished data). In contrast, transcripts for both CCL19 and
CCL21 were readily detected in arteries from patients with
PMR, supporting the finding that DCs in these tissues are
no longer resting. Concentrations of CCL19 and CCL21
mRNA copies in the arteries from the PMR patients did
not reach the levels found in full-blown vasculitis. In the
samples with fully developed GCA, copies for CCL19
were increased eightfold above controls (median of 1,543
copies), and copies for CCL21 were 24-fold higher (me-
dian of 7,662 copies) than in normal arteries. In immuno-
Figure 1. DCs in normal and
inflamed temporal arteries. Tem-
poral arteries were collected from
diagnostic biopsies. Patients with
granulomatous inflammatory infil-
trates were categorized as having
GCA. Patients were diagnosed
with PMR if they had a typical
clinical presentation but no vas-
cular infiltrates. Normal temporal
arteries were from patients who
had neither PMR nor GCA.
Paraffin-embedded arteries were
stained with anti–S-100 (A), an-
tifascin (B), or anti-CD11c Ab
(C) to identify DCs. Frozen sec-
tions were stained with anti-CD83
Ab to assess DC activation (D–F).
Normal temporal arteries contain
a population of S-100  (red),
fascin  (blue), and CD11c 
(brown) DCs positioned at the
adventitia–media border (A–C).
In noninflamed arteries, these
DCs lack CD83 (D). Numerous CD83  DCs (blue) participate in the granulomatous lesions in GCA (E). In arteries from patients with PMR, adventitial
DCs have acquired the activation marker CD83 (F). Original magnification, 200 (D–F) and 400 (A–C).
Figure 2. Tissue production of CCL19 and CCL21 in temporal arteries
from patients with GCA or PMR and in normal arteries. Temporal arteries
were collected, and cDNA was generated. Transcripts for  -actin,
CCL19 (top), and CCL21 (bottom) were determined by quantitative
PCR. cDNA concentrations were adjusted to 2   105  -actin copies.
The number of chemokine transcripts is presented as box plots, with the
median and 25th and 75th percentiles as the box, and the whiskers signify
the 10th and 90th percentiles. Normal arteries contained minimal copies
of CCL19 and CCL21 mRNA. Abundant transcripts for both chemo-
kines were present in arteries with GCA. Arteries from patients with
PMR, despite the lack of inflammatory infiltrates, contained intermediate
numbers of CCL19 and CCL21 mRNA transcripts.Ma-Krupa et al. 177
histochemical studies, the major source of CCL19 and
CCL21 protein was CD83  DCs (unpublished data).
These data suggest that adventitial DCs in normal arteries
are immature and resting. In PMR, the arterial DCs have
undergone activation despite the absence of an inflammatory
infiltrate. Fully developed granulomatous lesions include a
population of highly activated chemokine-producing DCs.
Treatment with CD83-Specific Antibodies Suppresses Arteritis.
To investigate how DCs contribute to the disease process,
we treated temporal artery–SCID mouse chimeras with
Figure 3. Therapeutic effects
of depleting CD83  DCs in
GCA. Temporal artery–SCID
mouse chimeras were generated
by implanting SCID mice with
segments from a GCA-affected
temporal artery. The chimeras
were injected on days 9–11 with
anti-CD83 Ab or control Ig, and
arterial grafts were harvested 1
wk later. Frozen tissue sections
were immunostained with anti-
CD3 Ab (A). The density of ar-
terial wall T cell infiltrates was
determined by counting CD3 
T cells (brown) on cross sections
of the arteries (B). cDNA was
generated from the explanted
temporal arteries to quantify
transcripts for  -actin, IFN- ,
and IL-1  by quantitative PCR.
All cDNA concentrations were
adjusted to 2   105  -actin copies.
Copy numbers of IFN- – and
IL-1 –specific sequences are shown as box plots as described in Fig. 2. Results are from five experiments with tissues from five different patients. Treatment
with anti-CD83 Ab induced massive loss of tissue-infiltrating T cells. In parallel, IFN-  mRNA transcripts decreased to  20% of baseline, and IL-1 
mRNA transcripts decreased by  75% (C). Original magnification, 400.
Figure 4. Functional character-
istics of arterial wall DCs in normal
arteries. Temporal arteries were
collected from patients with neither
GCA nor PMR. Tissue extracts
from fresh shock-frozen samples
were analyzed for TLR2- and
TLR4-specific sequences by PCR.
All negative arteries (marked as 1–6)
contained mRNA transcripts for
TRL2 and TLR4 (A). To test the
responsiveness of arterial DCs to
triggering with blood-born TNF- 
or TLR ligands, we implanted
pieces of arteries into SCID mice.
7–10 d after implantation, the
SCID mouse chimeras were injected
with 2  g i.v. TNF- , 10  g i.v.
LPS, or 100  l i.p. CFA, and the
arterial grafts were harvested 48 h
later. Tissue extracts from the ex-
planted grafts were analyzed for
the mRNA transcripts of  -actin,
CD83, IL-18, and the chemokines
CCL18, CCL19, and CCL21.
After stimulation with blood-born
triggers, arterial wall DCs ex-
pressed CD83  and began to pro-
duce an array of chemokines. The
effect of TNF-  was limited to the
induction of CCL21, whereas LPS induced the full spectrum of chemokines. One experiment representative of three is shown (B). Immunohistochem-
istry confirmed that arterial DCs from LPS-treated (left), but not control (right), arteries expressed CD83 (blue) and produced CCL21 (red) (C). Original
magnification, 200 (except LPS-treated CD83 and CCL21 images, which were 600 ). P, positive PCR control; N, untreated mouse control; and W,
negative PCR control.Dendritic Cells in Giant Cell Arteritis 178
anti-CD83 Ab. Expression of the CD83 marker in the vas-
culitic lesion was strictly limited to DCs (Fig. 1, E and F;
reference 15). Temporal arteries from five patients were di-
vided into three to five equal pieces. Mice carrying tissue
from the same donor were injected with either control Ig
or anti-CD83 Ab. Chimeras received Ab injections on days
9–11 after implantation, and the grafts were harvested 1 wk
after the completion of the treatment. Histomorphological
evaluation showed that anti-CD83 Ab treatment had a
marked effect on the density of the T cell infiltrate (Fig. 3,
A and B). After treatment with anti-CD83 Ab, the granu-
lomatous microstructures were destroyed and few T cells
were still present in the arterial wall. The remaining T cells
were dispersed throughout the vascular tissue. To examine
the effect on T cell and macrophage activity, cDNA was
generated from tissue extracts, and transcript levels for
IFN-  and IL-1  were semi-quantified. After the adminis-
tration of anti-CD83 Ab, levels of IFN-  transcripts, re-
flective of in situ T cell activation, decreased to  20% of
those measured in the grafts from animals treated with con-
trol Ig (Fig. 3 C). In parallel, the production of IL-1 ,
which is derived from macrophages in the vascular lesions,
decreased to  300 copies. Thus, targeting CD83  DCs
was highly effective in suppressing vasculitis, suggesting
that T cell activation is strictly dependent on DC function.
Triggering of Arterial Wall DCs In Vivo.  Considering
the critical role of DCs in the vasculitic response, we
wanted to explore whether DCs indigenous to the adventi-
tia that are physiologically in a resting state could be stimu-
lated to differentiate in vivo. DCs respond to their mi-
croenvironment through a number of different receptors,
of which TLRs play an important role (25). To determine
the TLR profile expressed by adventitial DCs under nor-
mal conditions, we amplified by PCR tissue extracts from
normal temporal arteries with primers specific for TLR2
and TLR4. TLR2- and TLR4-specific sequences were
present in all normal temporal arteries (Fig. 4 A). To exam-
ine DC activation in vivo, temporal arteries from patients
who had neither GCA nor PMR were engrafted into
SCID mice, and the chimeras were injected with a panel of
mediators known to activate DCs. The temporal arteries
were explanted and analyzed for transcripts typically pro-
duced by activated DCs.
As shown in Fig. 4 B, DCs in untreated arterial grafts re-
mained immature, lacking CD83, IL-18, CCL18, CCL19,
and CCL21. If the SCID mouse chimeras were injected
with TNF- , LPS, or CFA, the DCs began to differentiate,
and each stimuli produced a different pattern of activation
markers. Arteries harvested from the TNF- –treated chi-
meras contained CD83- and CCL21-specific transcripts. A
broader spectrum of DC products, including CCL19,
CCL21, and IL-18 could be obtained if the chimeras were
treated with CFA. Optimal DC activation was achieved
with LPS, which was the most efficient in the induction of
CD83, IL-18, CCL18, CCL19, and CCL21. Immunohis-
tochemistry confirmed that these products derived from ar-
terial DCs. Fig. 4 C shows arterial tissue explanted from
LPS-treated and sham-treated SCID chimeras. LPS treat-
ment induced the expression of CD83 and CCL21 selec-
tively in DCs at the adventitia–media border. These exper-
iments established that blood-born stimuli could reach DCs
in the adventitia and induce maturation.
To investigate whether triggering of adventitial DCs
was sufficient to establish T cell responses in the arterial
wall,  normal temporal arteries were selected from HLA-
DRB1*0401  donors. The arteries were implanted into
SCID mice, and 6 d later, the mice were injected with LPS.
30 h after the LPS injection, 5   106 HLA-DRB1*0401–
specific alloreactive human T cell clones were adoptively
transferred into the chimeras. The arteries, which were
explanted 18 d after implantation, were enlarged and sur-
rounded by highly inflamed perivascular tissue. Immuno-
histochemistry demonstrated the accumulation of tissue-infil-
trating human T cells in the graft (Fig. 5, A and B). Human
CD3  T cells accumulated in the proximal adventitia and in
the distal media, the site of DC localization. In contrast,
adoptive transfer of alloreactive human T cell clones without
prior LPS administration was not sufficient to induce the re-
tention of human T cells in the artery wall (Fig. 5 D).
To determine whether the cotreatment with LPS and
human T cells had indeed resulted in the activation of tis-
Figure 5. Activated arterial DCs are capable of stimulating T cells.
Temporal artery–SCID mouse chimeras were generated by implanting
normal temporal arteries from HLA-DRB1*0401  donors. 6 d after
implantation, the chimeras received 10  g LPS or PBS i.v., and 30 h
later, 5   106 alloreactive human T cell clones specific for HLA-
DRB1*0401 or T cell lines derived from arterial tissue of patients with
GCA were adoptively transferred into the mice. Arterial grafts were
explanted and embedded in OCT. To locate human T cells in the arterial
grafts, frozen tissue sections were immunostained with anti-CD3 Ab.
One experiment representative of five is shown. CD3  T cells (brown)
were found in the arteries explanted from the chimeras that had been
treated with LPS and had received the T cells. Tissue-infiltrating T cells
accumulated along the adventitia–media junction (A and B). In the absence
of LPS pretreatment, human T cells were rarely detected in the arteries
(D). Grafts from animals that had received neither LPS nor T cells were free
of human T cells (C). Original magnification, 200 (A, C, and D) and 400 (B).Ma-Krupa et al. 179
sue-resident DCs and the recruitment and retention of al-
lospecific T cells, markers of T cell and DC activation were
quantified in explanted temporal arteries. As shown in Fig.
6, in the absence of LPS and T cell transfer, no CD83 and
minimal levels of IL-18 were found. Adoptive transfer of
the T cell clones alone caused a minor induction of CD83.
When LPS stimulation preceded T cell transfer, both
markers of DC activation, CD83 and IL-18, were up-regu-
lated. Similar results were obtained for IFN-  and CD40L,
markers for T cell activation in the tissue. Production of
IFN-  as well as CD40L required the sequential treatment
with LPS followed by the adoptive transfer of T cells.
These experiments demonstrated that triggering of adventi-
tial DCs was sufficient to induce T cell recruitment, reten-
tion, and stimulation in the arterial wall.
Induction of Vasculitis in Arteries with Activated DCs from
Patients with PMR.  The expression of CD83 on adventi-
tial DCs and the production of chemokines in arteries from
patients with PMR suggested that this disease entity is asso-
ciated with DC activation, yet a detectable infiltrate of T
cells and macrophages has not been established. To exam-
ine whether DCs in PMR arteries are indeed activated and
have the potential to stimulate T cells, we developed an ex-
perimental system that allows for the in vivo transfer of T
cells from GCA arteries into arteries lacking T cell infil-
trates. Temporal arteries from patients who had unrelated
diseases, patients who had PMR, and patients with typical
granulomatous infiltrates of GCA were HLA-DR geno-
typed. We selected arteries that were HLA-DRB1*0401 .
This allele is associated with both GCA and PMR and is
present in 60–70% of the patients and in 20–25% of the
controls. Temporal arteries were cut into two pieces, and
SCID mice were implanted with a single arterial specimen
from a control donor, a patient with PMR, or a patient
with GCA, or they were implanted with a combination of
arteries from all three patients. After 7 d, the grafts were
explanted and examined for T cell activation. Representa-
tive results from three such coimplantation experiments are
shown in Fig. 7.
T cells from the GCA lesions invaded the arteries from
the HLA-DRB1–matched patients with PMR but could
not be found in HLA-DRB1–matched normal temporal
arteries (Fig. 7 A). Not only were T cells recruited to the
PMR arteries, but they underwent in situ activation. As re-
ported previously (6, 14), arteries with GCA contained
high copies of IFN- ; IFN-  could not be found in nega-
tive arteries and arteries from patients with PMR (Fig. 7
B). Coimplantation of arteries from all three donor subsets
resulted in the rapid induction of IFN-  in the PMR arter-
ies. Negative arteries were unaltered even when implanted
together with inflamed arteries. The only source of human
T cells in the SCID mice was the temporal arteries from
the patients with GCA. T cells from these inflamed arteries
moved to the PMR arteries but avoided the negative arter-
ies. DCs and macrophages from the GCA artery apparently
did not migrate to the normal artery in a sufficient number
to sensitize this normal tissue for a T cell response. Al-
though the evidence is indirect, the selectivity of the re-
sponse to PMR arteries implicates the activated resident
DCs in the PMR arteries as the driving force. Quantifica-
tion of CD40L sequences, which are specifically produced
by activated T cells, confirmed the migration of human T
cells from the GCA to the PMR arteries, where they un-
derwent stimulation (Fig. 7 C). Again, negative arteries re-
mained free of activated T cells. Thus, adventitial DCs in
patients with PMR have undergone activation and are ca-
pable of interacting with T cells, specifically T cells that
have accumulated in the vascular lesions of GCA.
Discussion
Data presented here provide compelling evidence for a
crucial role of DCs in the pathogenesis of GCA. First, we
have demonstrated that an indigenous population of DCs
resides in the adventitia of medium-size arteries. These DCs
are immature and lack the ability to stimulate T cells. Analy-
sis of temporal arteries from patients with PMR confirmed
that activation of adventitial DCs is a critical early step in
Figure 6. Stimulation of adoptively transferred T
cells by activated arterial DCs. Temporal artery–SCID
mouse chimeras carrying HLA-DRB1*0401  normal
arteries were treated with LPS and adoptively trans-
ferred with alloreactive human T cells as described in
Fig. 5. Explanted arterial grafts were shock frozen and
used for the generation of cDNA. cDNA concentra-
tions were adjusted to 2   105   -actin transcripts.
Tissue concentrations of  -actin, CD83 (A), IL-18
(B), IFN-  (C), and CD40L (D) mRNA transcripts
were determined by quantitative PCR. Pretreatment
with LPS induced prompt activation of DCs as indi-
cated by the up-regulation of CD83 and IL-18
mRNA transcripts. IFN- –and CD40L-specific
mRNA transcripts were clearly induced in arteries
that had been pretreated with LPS and that received
human alloreactive T cell clones. In the absence of
LPS stimulation, adoptively transferred T cells induced
a minimal up-regulation of CD83, but they failed to
undergo in situ activation.Dendritic Cells in Giant Cell Arteritis 180
vasculitis that precedes the recruitment of T cells and macro-
phages into the vascular wall. Triggering of adventitial DCs
by blood-born pathogen-associated molecular patterns, such
as LPS, is sufficient to initiate in situ T cell stimulation and
to break the immune tolerance in the perivascular space. Ac-
tivated arterial DCs remain the key antigen-presenting cell
in the vascular lesions of GCA, as shown by the depletion of
CD83  cells, which essentially abrogated vasculitis. We pro-
pose that adventitial DCs are primarily tolerogenic and pro-
tect the vessel wall from potentially devastating immune
responses. Their activation is a seminal event in the estab-
lishment of a misplaced T cell response, leading to granu-
loma formation and arterial wall destruction.
DCs are powerful antigen-presenting cells, and it comes
as no surprise that they have a role in stimulating T cells in
granulomatous lesions. However, it was unexpected that
treatment with anti-CD83 Ab virtually eliminated the in-
flammation in the artery. Highly activated macrophages are
abundantly present in the arterial wall infiltrates (8, 26), and
numerous microvessels are being formed (12). Nevertheless,
interaction with T cells seems to be limited to DCs and does
not involve endothelial cells, macrophages, or smooth mus-
cle cells. CD83  DCs are the only cell population in the
vasculitic lesions that express CD86, thereby giving them
the costimulatory molecules necessary to interact with tis-
sue-invading T cells (15). The unique position of DCs in
stimulating T cells even in chronic inflammatory lesions al-
lows for unparalleled therapeutic possibilities.
Even more interesting than the contribution of fully ma-
ture DCs in established vasculitis is the role of immature
DCs in healthy arteries. In healthy arteries, S-100  fascin 
CD11c  DCs typically reside at the adventitia–media bor-
der. The adventitia of large blood vessels has traditionally
been considered a support tissue, but it may have an ex-
panded role in the immunosurveillance of the perivascular
space. Adventitial DCs have characteristic features of im-
mature DCs: they lack CD83; they do not produce che-
mokines, including IL-18; and HLA class II molecules are
not up-regulated (unpublished data). We tested the capa-
bility of arterial DCs to serve as allostimulators and found
that they did not trigger in situ stimulation of adoptively
transferred T cells. In principal, they were capable of allo-
stimulation, and triggering by LPS was sufficient to turn
them into competent partners for T cells. Considering their
phenotype and their functional capabilities in vivo, arterial
DCs may primarily function in preventing T cell responses.
A similar functional profile has been reported for hepatic
DCs, and it has been proposed that liver tolerogenicity is
related to specialized DCs (27, 28).
Hallmark studies by Steinman and colleagues (29–32)
have established that DCs are critically involved in the in-
duction of peripheral tolerance. Although the underlying
mechanisms are not entirely clear, it is assumed that pre-
serving the immaturity of DCs is fundamentally important
for tolerance induction. Under steady state conditions, DCs
resident in peripheral tissues internalize self-antigens, fol-
lowed by DC migration and presentation of self-peptides
to T cells in the lymph nodes. Immature DCs may control
peripheral tolerance by inducing the differentiation of reg-
ulatory human T cells (33, 34). The concept of controlling
peripheral tolerance may be particularly important when it
comes to the perivascular space. The vulnerability of blood
vessels to inflammatory destruction and the potential lethal
consequences of blood vessel damage emphasize the need
for preventing immune responses in the perivascular space.
Even when foreign and potentially harmful antigens are en-
Figure 7. DC activation in PMR arteries is sufficient to activate disease-
relevant T cells from GCA arteries. Donors of normal arteries and patients
with PMR or GCA were typed for HLA-DR, and HLA-DRB1*0401 
arteries were selected. Arteries from patients with each diagnosis were
implanted individually into SCID mice or three arteries (one from each
disease category) were implanted into nonadjacent sites of the same mouse.
After 7 d, the grafts were harvested, shock frozen, and used for the genera-
tion of cDNA. cDNA concentrations were adjusted to equal numbers of
 -actin copies. One experiment representative of three is shown. Tissue-
infiltrating T cells were detected by PCR analysis for TCR-  sequences
(A). T cell activation in the tissues was assessed by quantifying mRNA
transcripts for IFN-  (B) and CD40L (C) by quantitative PCR. GCA
arteries contained abundant TCR-  mRNA (lane 1). No T cells were
detected in negative arteries (lanes 4 and 5), which remained free of TCR- 
sequences even after coimplantation with inflamed arteries (lane 4). PMR
arteries had a minimal signal for TCR-  if implanted individually (lane 3),
but they accumulated TCR-  copies when combined with inflamed
arteries (lane 2). No IFN-  or CD40L could be detected in negative arter-
ies. PMR arteries remained negative for IFN-  and CD40L as long as they
were isolated from arteries with typical vasculitic lesions. Once GCA and
PMR arteries were combined in the same chimera, T cells from the vascu-
litic infiltrates migrated into the PMR arteries, where they produced IFN- 
and CD40L (B and C). Copy numbers of IFN-  and CD40L are shown as
mean   SD for one representative experiment. P, positive PCR control;
W, negative PCR control.Ma-Krupa et al. 181
countered in the vascular wall, it may be more beneficial to
the host to prevent immune responses at any price. In that
sense, the large arteries should be considered a territory de-
sirable to be protected by immune privilege, comparable to
the eyes or the testes (35, 36).
When DCs encounter antigen in the context of tissue in-
jury and/or inflammation, they enter a program of mat-
uration in which their phagocytic properties are down-
regulated and their antigen-processing and -presentation
machinery is up-regulated (37, 38). Also, they modify their
profile of chemokine receptors and migrate toward second-
ary lymphoid tissues via lymphatics (39, 40). Such a report-
ing mechanism appears to be functional for temporal arteries
as well because identical CD4  clonotypes have been iso-
lated from the right and the left temporal arteries, suggesting
central priming and seeding of T cells to the vasculitic infil-
trate (5). Experiments in SCID mouse chimeras implanted
with normal temporal arteries demonstrated that the imma-
ture state of arterial DCs could easily be overcome; circulat-
ing LPS was sufficient to drive tissue DCs into maturation
and to prepare them to stimulate T cells. After arterial DCs
were exposed to blood-born LPS, T cells were recruited to
the artery and underwent stimulation, which was evident by
the induction of CD40L and IFN- . Triggering with LPS
induced retention of T cells in the arterial wall; under phys-
iologic conditions, the vascular wall of medium-size arteries
is free of any T cells and macrophages.
Once activated, tissue DCs leave the tissue site to initiate
priming in the lymph node and to limit the duration of a
localized inflammatory response. Surprisingly, the activa-
tion of arterial wall DCs, such as in patients with PMR or
fully developed GCA, was not necessarily associated with
their migration out of the tissue. Instead, DCs in the PMR
arteries remained at the adventitia–media junction. In fully
evolved arteritis, DCs were part of the granulomatous for-
mation (15, 40). DCs in arteritic lesions express CCR7 (15)
and release the CCR7-binding chemokines CCL19 and
CCL21. This could possibly lead to a trapping of DCs in
the lesions. PMR arteries do not contain CCR7 mRNA,
suggesting a different mechanism of retaining activated
DCs in the peripheral tissue.
Maturation of adventitial DCs could be a consequence
of, not a cause for, T cell responses evolving in the arterial
wall. To address this important question, we made use of
an interesting clinical model. Temporal arteries from pa-
tients with PMR are free of inflammatory infiltrates (6).
Arterial DCs in such arteries expressed the CD83 activation
marker and produced CCL19 and CCL21 (Figs. 1 and 2).
More importantly, when HLA-DR–matched temporal ar-
teries from patients with GCA and PMR were coim-
planted, T cells were recruited into the noninflamed PMR
arteries and began to produce IFN-  and CD40L. Under
the same experimental conditions, temporal arteries from
patients without PMR or GCA remained protected from T
cell responses. These findings are best compatible with the
model that the chain of events leading to vasculitis has been
initiated in PMR but that T cells interacting with activated
arterial DCs are not present. In contrast, in patients with
fully developed GCA, such T cells accumulate in the arte-
rial wall layers and orchestrate the generation of granulo-
mas. This model is consistent with clinical observations and
with prior papers on the nature of the subclinical inflam-
matory response in PMR (6, 14). Approximately 10% of
patients diagnosed with PMR will eventually progress to
GCA (17, 41). Also, IFN-  is strictly absent from PMR ar-
teries, but low levels of IL-2 are found (6). Whether the
failure of activated DCs in PMR arteries to attract T cells
reflects a genuine difference in the T cell repertoire of pa-
tients with PMR or GCA needs to be investigated.
When given the opportunity in the coimplantation ex-
periments, T cells made the transit from the GCA artery
into the PMR artery, suggesting that the relevant antigen is
available in PMR arteries (42). These results confirm prior
conclusions that T cell clones isolated from inflamed tem-
poral arteries proliferate when driven with tissue extracts
from GCA arteries and also from PMR arteries. The nature
of such a shared antigen has remained elusive. As in most
autoimmune syndromes, unidentified and/or unknown in-
fections have been suspected to be the instigators. Multiple
papers have suggested that viral or bacterial materials can be
found in temporal artery sections (43–46), but attempts to
confirm such papers have failed (47, 48). Data presented
here would fit with an infection breaking the resting state
of adventitial DCs and initiating disease. It seems that the
site of infection does not necessarily need to be in the ar-
tery. Adventitial DCs were highly responsive to blood-
born TLR ligands. Interestingly, stimulation with TNF- 
could only partially activate the arterial DCs. CFA, known
to trigger TLR2, was more potent that TNF- , and LPS
was the most effective in inducing DC activation, which
was followed by T cell recruitment and stimulation. Under
physiologic conditions, adventitial DCs do not express
CD14, which is considered to be instrumental in mediating
an LPS signal (49, 50). We have preliminary data that
CD14 is up-regulated in the arterial wall after LPS injec-
tion (unpublished data).
GCA and PMR are currently managed with corticoste-
roid therapy (17, 51), which is highly effective and results
in symptomatic improvement within hours to days. The
promptness of the corticosteroid-induced improvement has
been cited as a diagnostic criterion for both syndromes. In-
hibition of NF- B has been shown to be important in me-
diating immunosuppression in GCA (22, 52). Therefore,
TLR-induced activation of the innate immune system
should be explicitly sensitive to the therapeutic effects of
corticosteroids. One of the shortfalls of corticosteroid ther-
apy is the requirement to maintain immunosuppression
over several years, thereby increasing the risk of unwanted
side effects. Data presented here would encourage the de-
velopment of alternative therapeutic interventions targeted
at the DCs in early and late vascular lesions.
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